|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM20A |
Gene summary for FAM20A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM20A | Gene ID | 54757 |
| Gene name | FAM20A golgi associated secretory pathway pseudokinase | |
| Gene Alias | AI1G | |
| Cytomap | 17q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | B7Z4Y3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54757 | FAM20A | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 4.25e-03 | 7.57e-01 | -0.138 |
| 54757 | FAM20A | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 5.52e-11 | 5.61e-01 | -0.2116 |
| 54757 | FAM20A | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.84e-04 | 5.87e-01 | -0.2107 |
| 54757 | FAM20A | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.64e-09 | 4.78e-01 | -0.2119 |
| 54757 | FAM20A | RNA-P3T-P3T-4 | Human | Lung | IAC | 1.09e-02 | 2.31e-01 | 0.1859 |
| 54757 | FAM20A | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.64e-09 | 4.09e-01 | -0.0166 |
| 54757 | FAM20A | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 8.22e-13 | 4.46e-01 | -0.0132 |
| 54757 | FAM20A | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.31e-11 | 4.74e-01 | -0.013 |
| 54757 | FAM20A | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.26e-10 | 4.62e-01 | -0.0121 |
| 54757 | FAM20A | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.14e-04 | 5.45e-01 | -0.0961 |
| 54757 | FAM20A | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.71e-10 | 6.87e-01 | -0.0876 |
| 54757 | FAM20A | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.24e-04 | 6.50e-01 | -0.0822 |
| 54757 | FAM20A | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 3.51e-05 | 4.89e-01 | -0.0809 |
| 54757 | FAM20A | male-WTA | Human | Thyroid | PTC | 7.30e-12 | 2.54e-01 | 0.1037 |
| 54757 | FAM20A | female-WTA | Human | Thyroid | PTC | 8.84e-09 | 5.19e-01 | 0.0726 |
| 54757 | FAM20A | PTC01 | Human | Thyroid | PTC | 6.92e-24 | 7.31e-01 | 0.1899 |
| 54757 | FAM20A | PTC04 | Human | Thyroid | PTC | 6.92e-24 | 6.12e-01 | 0.1927 |
| 54757 | FAM20A | PTC05 | Human | Thyroid | PTC | 3.34e-30 | 1.07e+00 | 0.2065 |
| 54757 | FAM20A | PTC06 | Human | Thyroid | PTC | 2.10e-38 | 1.11e+00 | 0.2057 |
| 54757 | FAM20A | PTC07 | Human | Thyroid | PTC | 6.59e-21 | 4.77e-01 | 0.2044 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00719006 | Lung | IAC | regulation of protein serine/threonine kinase activity | 71/2061 | 359/18723 | 6.33e-07 | 3.72e-05 | 71 |
| GO:00458607 | Lung | IAC | positive regulation of protein kinase activity | 72/2061 | 386/18723 | 4.89e-06 | 1.96e-04 | 72 |
| GO:00719024 | Lung | IAC | positive regulation of protein serine/threonine kinase activity | 44/2061 | 200/18723 | 5.16e-06 | 2.04e-04 | 44 |
| GO:00336748 | Lung | IAC | positive regulation of kinase activity | 83/2061 | 467/18723 | 6.76e-06 | 2.45e-04 | 83 |
| GO:003367412 | Lung | AIS | positive regulation of kinase activity | 77/1849 | 467/18723 | 4.67e-06 | 2.31e-04 | 77 |
| GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
| GO:007190012 | Lung | AIS | regulation of protein serine/threonine kinase activity | 61/1849 | 359/18723 | 1.76e-05 | 6.17e-04 | 61 |
| GO:007190211 | Lung | AIS | positive regulation of protein serine/threonine kinase activity | 38/1849 | 200/18723 | 6.00e-05 | 1.65e-03 | 38 |
| GO:003367421 | Lung | AAH | positive regulation of kinase activity | 28/613 | 467/18723 | 1.63e-03 | 3.96e-02 | 28 |
| GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
| GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
| GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
| GO:007190210 | Thyroid | PTC | positive regulation of protein serine/threonine kinase activity | 93/5968 | 200/18723 | 1.01e-05 | 1.12e-04 | 93 |
| GO:007190025 | Thyroid | ATC | regulation of protein serine/threonine kinase activity | 176/6293 | 359/18723 | 8.35e-10 | 2.17e-08 | 176 |
| GO:004586026 | Thyroid | ATC | positive regulation of protein kinase activity | 185/6293 | 386/18723 | 3.00e-09 | 7.02e-08 | 185 |
| GO:003367427 | Thyroid | ATC | positive regulation of kinase activity | 212/6293 | 467/18723 | 5.89e-08 | 1.05e-06 | 212 |
| GO:007190215 | Thyroid | ATC | positive regulation of protein serine/threonine kinase activity | 96/6293 | 200/18723 | 1.63e-05 | 1.51e-04 | 96 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM20A | SNV | Missense_Mutation | rs147626178 | c.686N>T | p.Ser229Leu | p.S229L | Q96MK3 | protein_coding | tolerated(0.1) | benign(0.025) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM20A | SNV | Missense_Mutation | novel | c.862N>A | p.Val288Ile | p.V288I | Q96MK3 | protein_coding | tolerated(0.45) | benign(0.007) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| FAM20A | SNV | Missense_Mutation | rs779624390 | c.1340C>T | p.Ser447Leu | p.S447L | Q96MK3 | protein_coding | deleterious(0.03) | benign(0.284) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| FAM20A | SNV | Missense_Mutation | c.668N>G | p.Lys223Arg | p.K223R | Q96MK3 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A0K2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Hormone Therapy | megace | SD | |
| FAM20A | SNV | Missense_Mutation | rs570338353 | c.829N>T | p.Arg277Trp | p.R277W | Q96MK3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM20A | SNV | Missense_Mutation | c.1532N>T | p.Gly511Val | p.G511V | Q96MK3 | protein_coding | tolerated(0.14) | benign(0.096) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM20A | SNV | Missense_Mutation | novel | c.1489G>A | p.Ala497Thr | p.A497T | Q96MK3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM20A | SNV | Missense_Mutation | rs747920001 | c.1573N>A | p.Gly525Ser | p.G525S | Q96MK3 | protein_coding | tolerated(0.14) | benign(0.146) | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM20A | SNV | Missense_Mutation | novel | c.611C>T | p.Ala204Val | p.A204V | Q96MK3 | protein_coding | deleterious(0.02) | benign(0.158) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM20A | SNV | Missense_Mutation | c.915C>A | p.Phe305Leu | p.F305L | Q96MK3 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |